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Neonatal chronic lung disease in the preterm infant, i.e. bronchopulmonary dysplasia (BPD) is characterized by
impaired pulmonary development with its effects persisting into adulthood. Triggered in the immature lung by
infectious complications, oxygen toxicity and the impact of mechanical ventilation, a sustained inflammatory
response, extensive remodeling of the extracellular matrix, increased apoptosis as well as altered growth factor
signaling characterize the disease. The current review focuses on selected pathophysiologic processes and their
interplay in disease development. Furthermore, the potential of both, acute and long-term changes to the pulmonary
scaffold and the cellular interface in concert with dysregulated growth factor signaling to affect aging and repair
processes in the adult lung is discussed.
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With the increasing number of extremely premature
preterm infants discharged from neonatal intensive care
over the last decades, the development of neonatal
chronic lung disease (nCLD), also known as bronchopul-
monary dysplasia (BPD), accounts for a significant num-
ber of all pulmonary diseases in early infancy. Although
major advances were made with respect to perinatal
care, including surfactant replacement therapy, induc-
tion of lung maturation by antenatal corticosteroids, and
improved invasive and non-invasive ventilation strat-
egies, the incidence of BPD has not changed over the
last decade [1]. Due to differences in patient population
and infant management practices, numbers vary between
newborn care centers and reach up to 68% in the group
of infants between 22 and 28 weeks of gestation [2]. For
Europe, the MOSAIC study group found 10% to 20% of
all infants born between 23 and 31 weeks postmenstrual
age (PMA) to develop BPD [3].
The disease results in adverse long-term pulmonary out-
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distribution, and reproduction in any medium,with an increased risk for coexistent impairments in neu-
rocognitive development underlining the importance of
BPD on morbidity in this patient population [4].
Clinically, BPD is defined by the need for supplemental
oxygen and/or ventilator support for greater than 28 days
(mild) or beyond 36 weeks PMA (moderate and severe) [5].
Symptoms are primarily due to alveolar hypoventilation
and an impaired respiratory gas exchange, with hypoxemia
and hypercapnia resulting in increased work of breathing
and clinical signs of dyspnea. The mismatch of ventilation
and perfusion resulting from a reduction in alveolar surface
area as well as impaired vessel growth and function often
precedes the development of sustained impairments includ-
ing pulmonary hypertension, a common complication of
the disease [5]. Furthermore, survivors of BPD frequently
develop long-term respiratory morbidity, including in-
creased airway hyperreactivity and decreased lung function,
as well as a compromised pulmonary immune response,
resulting in a greater risk for hospital re-admission due to
respiratory tract infections in the first years of life [6].
Histopathological data from human tissue were mainly
obtained from the lungs of late preterm infants in the
pre-surfactant era, where the so called ‘old’ BPD was
characterized by fibrotic changes and the side-by-side of
over-inflation and atelectasis occurring after long-term
ventilation and exposure to high oxygen concentrations.pringer. This is an Open Access article distributed under the terms of the
reativecommons.org/licenses/by/4.0), which permits unrestricted use,
provided the original work is properly credited.
Niedermaier and Hilgendorff Molecular and Cellular Pediatrics  (2015) 2:2 Page 2 of 7Although some of the characteristics are still seen in pa-
tients that now benefit from prenatal steroid treatment
and surfactant therapy [7], the ‘new’ BPD is mainly char-
acterized by the combination of alveolar hypoplasia and
disrupted vascular development as well as saccular wall fi-
brosis, with minimal airway injury [8]. The histopatho-
logical picture is associated with sustained inflammatory
changes, extensive remodeling of the extracellular matrix,
and imbalanced growth factor signaling [9].
Clinical studies, supported by findings from experimental
models, have identified and confirmed both pre- and post-
natal risk factors associated with the characteristic impair-
ment in lung development observed in infants with BPD.
Key pathophysiologic mechanisms are triggered by infec-
tions occurring both in utero and ex utero [10], oxygen tox-
icity [11] and the impact of mechanical ventilation (MV)
[12]. These risk factors act on a functional and structural
immature lung beyond the individual genetic background,
with impaired pre- and postnatal somatic growth in concert
with hormonal dysregulation and male gender further add-
ing to the risk for BPD development [3,6,13].
This review will focus on key pathophysiologic mecha-
nisms leading to BPD, their interaction with one another,
and the potential contribution to long-term lung path-
ology. Figure 1 depicts a schematic overview of the
reviewed processes critical for disease development.
Review
Pathomechanisms
Intra-amniotic, congenital and nosocomial infections,
oxygen toxicity, and MV contribute to the onset and per-
petuation of an inflammatory response in the premature
lung, characterizing the development of BPD [10-12]. ThisFigure 1 Orchestration of risk factors and pathophysiologic variablesinflammatory process is indicated by the influx of neutro-
phils into the lung followed by macrophage recruitment
[10,14] as measured in the bronchoalveolar lavage (BAL)
fluid obtained from premature infants developing BPD.
The characteristic cytokine profile in the lungs of infants
developing BPD includes elevated levels of interleukin (IL-)
8, IL-1β, IL-6, tumour necrosis factor (TNF)-α, monocyte
chemo-attractant proteins, MCP-1, MCP-2 and MCP-3, as
well as the macrophage inflammatory proteins, MIP-1a and
MIP-1b and decreased expression of IL-10, pointing to-
wards a disturbed balance of pro- and anti-inflammatory
factors [10]. The recruitment and trans-endothelial migra-
tion of inflammatory cells is associated with the release of
enzymes with tissue-damaging effects, cellular apoptosis,
and the dysregulation of central signaling pathways in the
lung as indicated by an increase in transforming growth
factor (TGF)-β1 and the dysregulation of transcription fac-
tors such as nuclear factor (NF)-kB [10]. TGF-β activation,
observed induced by prenatal infections, oxygen exposure
as well as long- or even short term ventilation as observed
in newborn mice, induces apoptosis and alters both cell
proliferation and migration [15]. While activation of NF-kB
in the adult mouse is known to exhibit pro-inflammatory
effects often resulting in apoptosis, its role in the imma-
ture lung extends to anti-inflammatory as well as pro-
developmental properties [14,16]. The perturbation of
central signaling pathways by the described inflammatory
response is linked to the disruption of airway-branching
and impaired development of epithelial, mesenchymal
and endothelial cell structures, culminating in a failure
of lung development as shown in fetal mice [14,15].
Both, the presence of infections as well as the impact
of shear stress and oxygen toxicity, independentlywith anticipated treatment potential in the development of BPD.
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oping lung, due to the accentuated release from cellular
and matrix sources. Interestingly, in the newborn rat,
the impact of MV and hyperoxia leads to both common
and distinct extracellular matrix (ECM) changes with re-
spect to collagen deposition, increase in interstitial thick-
ness, and elastin content [11]. The (fatal) combination of
ECM remodeling together with the increase in apoptosis
and the decrease in lung cell proliferation [11] induced
by alterations in growth factor signaling [17], impairs
pulmonary epithelial, endothelial and mesenchymal cell
survival and differentiation, leading to disrupted alveolar
and capillary development.
Extracellular matrix
The lung extracellular matrix plays an essential role in
lung development since it functions as the scaffold for
developing alveoli and vessels [18]. Abnormalities in
lung ECM turnover and impaired structural organization
significantly contribute to the development of BPD as
shown by clinical and experimental studies. Scattered
elastin deposition, increased elastin breakdown and de-
fective septation are observed in infants with BPD and
in animal models of the disease, e.g. by the use of MV in
newborn mice [15]. The pathologic induction of ECM
breakdown is associated with increased tropoelastin pro-
duction and the scattered deposition of misassembled
elastic fibres in the lung [18]. Serine proteases (e.g. tryp-
sin), neutrophil proteases, matrix metalloproteinases
(MMP) and the papain family of proteases (e.g. cathep-
sin B, H, K, L and S) initiate and further regulate the re-
modeling process of the ECM. While expression of
proteases such as MMP-2 and -9 are needed to enable
cell migration and stimulate physiologic remodeling of
the ECM in the developing lung on the one hand [18],
excess secretion initiates disease pathology through ac-
centuated ECM breakdown resulting in the destruction
of the intact alveolo-capillary interface on the other [10].
In line with this, imbalanced expression of different
MMP subtypes is associated with BPD development
[10,18] and hyperoxia has been shown to increase pul-
monary MMP-9 activity in neonatal rat lungs [11], with
its expression heralding the chronic and regenerative
phase of BPD [18].
The indicated imbalance of pulmonary proteases and
their inhibitors in the immature lung can be attributed to
their enhanced release from the matrix, as well as an in-
creased production by resident cells such as smooth
muscle cells and inflammatory cells recruited to the in-
jured lung. In addition, the immaturity of the lung results
in the insufficient expression of anti-proteases. The result-
ing perpetuation of this remodeling process leads to im-
paired vessel development and alveolarization as well as
the reduction in functional abilities of different cell typesreflected by, i.e. decreased surfactant production and turn-
over [11]. Similarly, the increased presence of toxic oxygen
metabolites further stimulates the release of proteases
such as elastase, myeloperoxidase and xanthine oxidase
from the ECM as well as their activation [10,18]. These
processes are further enhanced by the relative deficiency
of anti-oxidants such as superoxide dismutase or gluta-
thione peroxidase rendering the immature lung to an
increased vulnerability to oxidative stress [10]. Patho-
logic ECM remodeling and the subsequent disruption
of the intact pulmonary scaffold development not only
hinders the formation of the alveolar and vascular net-
work but exceeds the effect of mere structural changes
by impacting cell fate [18].
Closely connected to the changes in the ECM, the
TGF-β superfamily, including the bone morphogenic
proteins (BMP), plays an important role in lung develop-
ment by influencing the cellular composition of the lung
via the regulation of endothelial and epithelial cell sur-
vival as well as influencing ECM production and remod-
eling [19]. TGF-β signaling, required for physiologic
lung development, is activated in the vascular and airway
smooth muscle and the alveolar and airway epithelium
throughout late lung development [20]. Primarily se-
creted by monocytes and macrophages recruited to the
lung, TGF-β can also be released from the ECM where la-
tent TGF-β binding proteins link TGF-β to the fibrillins.
An imbalance of signaling molecules of the TGF-β/BMP
signaling pathways has been described in various animal
models of BPD induced by the exposure to MV and/or
hyperoxia. In these models, excess TGF-β activation leads
to apoptosis and the imbalance of proliferation and migra-
tion in various cell types including endothelial cells and
(myo)fibroblasts alveolar and vascular hypoplasia charac-
terizing BPD [21].
Alveolarization
From the pseudoglandular to the canalicular stage of
lung development, the appearance of primary and sec-
ondary crests marks an essential step in lung growth.
Here, the epithelial-mesenchymal crosstalk is known
to be critically involved in the gradual process. The
resulting formation of new alveoli establishes the ap-
propriate interface with the developing capillary bed
allowing for sufficient gas-exchange [20]. In the con-
trary, lung architecture in BPD is characterized by al-
veolar simplification with a reduced number of
enlarged alveoli [5], caused by apoptosis of cells crit-
ical for alveolar and vessel formation as well as altered
cell fate and function in the face of extensive ECM
remodeling.
The (myo-) fibroblast, signaling through the platelet
derived growth factor (PDGF), is a critical driver of sec-
ondary septation including its contribution to elastin
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fore results in a failure of alveolarization indicated by an
emphysematous lung phenotype [18].
Other growth factors orchestrating the cross-talk between
the epithelial and mesenchymal cell compartment are
members of the fibroblast growth factor family (FGF),
essential mediators of alveolar morphogenesis and stimula-
tors of elastin synthesis [20]. Expressed by mesenchymal
cells, FGF-10 promotes the stereotyped sequence of lung
bud outgrowth and epithelial branching and proliferation
through tightly regulated signaling mechanisms [22]. FGF-7
stimulates proliferation of epithelial cells and appears to
play a role in the prevention of lung epithelial damage due
to external injury [18]. The disrupted process of secondary
septation as well as the malassembly of the elastic fiber
induced by MV and hyperoxia can in part be explained by
the perturbation of the FGF signaling pathway through the
activation of different inflammatory response variables, i.e.
NF-kB, IL-1β, TNF-a or toll-like receptors (TLR)-2 and
TLR-4 [18,22]. These inflammatory markers have been
shown to reduce FGF 10 expression in vitro which might
contribute to reduced and defective alveolar branching [22].
On the transcriptional level, epithelial cell survival and
differentiation is developmentally regulated by a multi-
tude of different factors including FOX proteins and
GATA6 [20]. In a baboon model of BPD using prema-
ture delivery and oxygen supplementation to induce dis-
ease pathology, the hypoxia-inducible factor (HIF) 1α,
but not HIF 2, was found to be downregulated in the
pulmonary tissue. Underlining its potential role in BPD
pathophysiology, stimulation of HIF by inhibition of HIF
degrading proteins in the same model promoted alveolari-
zation and angiogenesis thus leading to improved lung
function [23]. With respect to its cell specific effects, HIF,
in addition to activating downstream target genes that in-
crease oxygen delivery, acts on the vascular endothelial
growth factor (VEGF), well known for its role in mediating
angiogenesis, but furthermore exhibiting critical impact
on epithelial cell survival and differentiation, thereby influ-
encing surfactant production [17]. Thus, intrauterine
VEGF-treatment of HIF-2α-deficient newborn mice that
developed severe respiratory failure immediately after
birth, improved impaired gas exchange and respiratory
outcome by stimulating alveolar pneumocytes [24].
Angiogenesis
The vascular hypothesis establishes angiogenesis as a main
driver of alveolarization and therefore a critical process for
lung development [17]. The pulmonary capillary network
grows along the buds of newly developing airways and de-
veloping canalicular and saccular airspace structures. As
the airspaces grow larger in size, the capillary network ex-
pands through both sprouting and intussuscepted growth
[17]. An impairment of angiogenesis indicated by fewersmall vessels and their abnormal distribution, is mirrored
by a disturbed alveolar structure [5]. The role of vascular
development for alveolarization was further established in
different animal studies, where, the inhibition of angiogen-
esis by the use of specific antibodies or in knock-out mice
showed disabled VEGF expression or its down-stream sig-
naling to result in disruption of the alveolarization process
itself [17]. In keeping with these studies, the induction of
angiogenesis protects or enhances alveolarization in animal
models of BPD [21]. Reduced pulmonary expression of
endothelial markers in the human lung after short term
MV in contrast to reports of elevated endothelial markers
after long term ventilation may indicate compensatory
mechanisms or be the effect of fluctuating oxygen satur-
ation levels in the developing lung undergoing MV and
oxygen treatment [17].
The VEGF pathway is of particular importance in promot-
ing angiogenesis in the developing lung. This cell-specific
endothelial growth factor is a critical agent for vascular de-
velopment enabling formation and remodeling of pulmon-
ary vessels and alveolar structures. Its expression peaks
during the early stages of lung development and decreases
to adult levels in the last stage of alveolarization [17].
VEGF stimulates neovascularization at the leading edge of
the branching airways, thereby connecting the develop-
ment of blood vessels and airways, i.e. through the modu-
lation of FGF signaling [22]. Over-expression of VEGF in
the embryonic phase increases growth of pulmonary blood
vessels but in the same time disrupts the morphogenesis
of airway branches and alveolar type-I cell differentiation
[17]. Decreased VEGF levels have been found in preterm
infants who subsequently developed BPD [17], associated
with reduced pulmonary capillary volume and impaired
alveolarization in a mouse model of the disease [24]. In
different animal models, VEGF expression decreased upon
injury induced by hyperoxia, prolonged mechanical venti-
lation or endotoxin exposure [21]. Indicating a tight regu-
lation during development, induced pulmonary VEGF
levels were reported depending on the degree of hyperoxia
and some studies interpreted elevated VEGF levels as an
indicator of recovery from injury [11]. Destruction of al-
veolar septi in the adult lung after inhibition of VEGF sig-
naling underlines its importance as a pro-survival factor
[17]. Linking these changes back to ECM remodeling,
BMP family members have been shown to stimulate the
process of angiogenesis in the lung by increasing pro-
angiogenic signaling through increasing VEGF receptor
expression (VEGF-R2) [25], influencing pulmonary angio-
genesis via the wingless (Wnt) pathway at the same time
[26]. Abrogation of BMP signaling therefore likely leads to
compromised signaling in the VEGF pathway causing and
contributing to impaired lung development. Table 1 sum-
marizes the main findings derived from animal models
cited in this review.
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pathophysiologic understanding in BPD mainly relies on
the findings generated by the use of these and other ex-
perimental models in lambs, baboons, rats and mice try-
ing to mimic characteristic histopathological findings
while still mirroring important clinical conditions [7]. In
the mouse model, the induction of BPD by the impact of
moderate hyperoxia, i.e. 40% o2 and/or MV led to air
space enlargement with widened, hypercellular septae
and reduced number of alveoli and vessels [28]. Studies
in rats showed focal fibrotic sites next to perivascular,
interstitial, and alveolar edema upon MV [29]. Findings
from a baboon model of the disease using MV in ani-
mals of different GA to induce BPD pathology fostered
the ability to study different stages of the disease as well
as treatment settings with potential clinical relevance.
Whereas injury in more mature animals led to the devel-
opment of enlarged alveoli, increased edema and abnor-
mal abundance of elastin with only minor fibrotic
changes, more immature animals developed dysmorphic
microvasculature and varying degrees of fibroprolifera-
tion [30,31].
Nonetheless, although the histopathological findings in
animal models resemble the changes seen in human
lungs upon disease development, it has not been pos-
sible to fully imitate the pathological picture of BPD.
Long-term outcome
Clinically, patients with BPD often suffer from respiratory
exacerbations due to viral infections and asthma-like
symptoms such as airway hyper-responsiveness and im-
paired exercise intolerance [9]. In line with this, infants
with BPD require more frequent hospital readmissionsTable 1 Selection of animal models mimicking BPD
Study Species Mode of injury
Alvira et al. [27] Mouse (PN 5, 16 weeks) Intraperitoneal injection of l
Asikainen et al. [23] Baboons (E 125) MV at room air or with oxyge
as calculated by oxygenation
Blackwell et al. [14] Mouse (E 15) LPS in isolated macrophage
Bland et al. [15] Mouse (PN 5 to 7) MV at room air or with 40%
Compernolle et al. [24] Mouse (E 18.5) Transgenic mouse model (kn
Iosef et al. [16] Mouse (PN 6) Intraperitoneal injection of b
(BAY 11-7082)
Wallace et al. [12] Lambs (E 125 and 132) MV at room aircompared to preterms without BPD. Radiological findings
even in asymptomatic BPD survivors show changes in the
peripheral airways, with interstitial fibrotic changes still
present in the lungs of adult survivors of BPD [6].
Increasing evidence suggests that early pulmonary in-
jury leading to the pathophysiologic changes characteriz-
ing BPD may contribute to premature aging of the lung
[21]. The sustained and potentially irreversible alter-
ations of structure and function affecting both ECM as
well as epithelial, endothelial and mesenchymal cells
likely result in impaired pulmonary function including
the development of cardiovascular diseases, i.e. pulmon-
ary hypertension, often complicating the clinical course
of patients with BPD [6]. The scaffold provided by the
ECM seems to hold a ‘memory function’ , as studies
using decellularized lungs showed cell fate to be signifi-
cantly influenced by matrix composition, thereby indi-
cating long-term implications of ECM remodeling with
respect to pulmonary repair capacity and aging related
processes [6,32]. With respect to the pathophysiologic
changes observed in the pulmonary circulation, studies
in adult mice that outgrew oxygen supplementation in
the neonatal period suggest sustained changes in the
pulmonary vascular structure [11,21]. Furthermore, evi-
dence of increased oxidative stress was detected even in
adolescent patients with BPD, indicating that damage to
the developing lung may be associated with sustained
perturbations in the pulmonary oxidative stress response
[4]. The underlying differences in the equilibrium of sig-
naling pathways in the developing lung initiating and
prolonging pathophysiologic changes in patients with
BPD may persist during lung maturation and need to be
considered when treatment regimen are applied [27].Main finding
ipopolysaccharides (LPS) Persistent NF-kB activation in the fetal lung leads
to reduced inflammation and apoptosis 24 h
after LPS exposure in contrast to adult animals
n supplementation
index
Enhancement of angiogenesis by activation of
HIF improves lung growth and function
s Macrophage depletion or targeted inactivation
of the NF-κB signaling pathway protects airway
branching from adverse LPS effects
oxygen MV results in increased elastase activity, reduced
abundance of proteins regulating elastic fiber
assembly and scattered deposition of elastic
fibres in the lung
ock out of HIF 2α) Intrauterine delivery or postnatal intratracheal
instillation of VEGF stimulates surfactant synthesis
and reduces respiratory distress
locker of NF-κB NF-κB promotes physiological angiogenesis
and alveolarization in the developing lung
Increase in pulmonary pro-inflammatory cytokines
transcription
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sion in the fetal mouse lung via the NF-κB signaling
pathway is associated with impaired alveolarization and
may even result in epigenetic changes [14].
Conclusions
BPD is characterized by inflammation, apoptosis of various
cell types and extensive ECM remodeling. Three main risk
factors, i.e. pre- and postnatal infections, hyperoxia and
MV lead to the complex interaction of pro- and anti-
inflammatory proteins and the extensive alterations of sig-
naling pathways associated with growth factor imbalance.
Several in vitro and in vivo studies have contributed to our
understanding of molecular pathways involved in disease
development and their critical interplay, leading to the
identification of potential treatment targets. Most import-
antly, the use of experimental approaches and their (partial)
verification in clinical studies have connected critical path-
ways involved in the processes of angiogenesis, alveolariza-
tion and ECM remodeling in the context of BPD
development [21]. Although the indicated pathways impact
early postnatal lung development on different levels, it has
furthermore been demonstrated that the effects are not
only acute and time-restricted. In the contrary, permanent
changes in gene regulation and significant structural
changes, are causing long-term changes in pulmonary func-
tion [4]. Further studies are needed to study the effect of
promising treatment strategies with respect to their poten-
tial to influence long-term outcome. These studies have to
take the limitations of the experimental models into ac-
count that are widely used to generate our pathophysiologic
understanding.
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